Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 11/1/05 → 10/31/13 |
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic
- McDonagh, Kevin (PI)